Last reviewed · How we verify
NCT03396185
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer
Phase 2 trial testing Icotinib in EGFR Gene Mutation in 30 participants. Status unknown.
1 February 2022
Quick facts
| Lead sponsor | Betta Pharmaceuticals Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 9 May 2018 |
| Primary completion | 1 February 2022 |
| Estimated completion | 1 February 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Icotinib — full drug profile →
Conditions studied
- EGFR Gene Mutation — all drugs for EGFR Gene Mutation →
- Non Small Cell Lung Cancer Stage IIIA — all drugs for Non Small Cell Lung Cancer Stage IIIA →
- Non Small Cell Lung Cancer Stage IIIB — all drugs for Non Small Cell Lung Cancer Stage IIIB →
Sponsor
Betta Pharmaceuticals Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with EGFR Gene Mutation or Non Small Cell Lung Cancer Stage IIIA. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to evaluate the relapse free survival of patients who have EGFR-mutant stage IIIA-IIIB Non-small Cell Lung Cancer and receive Icotinib as consolidation therapy after synchronous or sequential chemoradiotherapy.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.
Amelia T, Kartasasmita RE, Ohwada T, Tjahjono DH. · · 2022 · cited 83× · PMID 35164092 · DOI 10.3390/molecules27030819 -
International consensus on severe lung cancer-the first edition.
Zhou C, Li S, Liu J, Chu Q, et al · · 2021 · cited 17× · PMID 34295668 · DOI 10.21037/tlcr-21-467 -
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity.
Lee CS, Sharma S, Miao E, Mensah C, et al · · 2020 · cited 8× · PMID 33117017 · DOI 10.2147/lctt.s258444 -
Targeted therapies for unresectable stage III non-small cell lung cancer.
Remon J, Hendriks LEL. · · 2021 · cited 6× · PMID 35118328 · DOI 10.21037/med-21-8
Verify or expand the search:
- PubMed search for NCT03396185
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Icotinib
Trials testing the same drug.
- NCT06517953 — Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations · Phase 2 · recruiting
- NCT05514314 — A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Dise · Phase 2 · unknown
- NCT05263947 — Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation · Phase 2 · completed
- NCT05132985 — Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma · Phase 2 · not yet recruiting
- NCT05104788 — A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell · Phase 2 · recruiting
Other recruiting trials for EGFR Gene Mutation
Currently open trials in the same condition.
- NCT06716580 — EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations · NA · recruiting
- NCT06222489 — Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT · Phase 2 · recruiting
- NCT06643000 — Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis · NA · recruiting
- NCT06186401 — Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells · Phase 1 · recruiting
- NCT06071013 — Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients · Phase 1, PHASE2 · recruiting
Other Betta Pharmaceuticals Co., Ltd. trials
Trials by the same sponsor.
- NCT07435038 — Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS · Phase 1, PHASE2 · not yet recruiting
- NCT07448116 — Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. · Phase 1, PHASE2 · recruiting
- NCT06641609 — A Phase I Study of CFT8919 in Patients With Advanced NSCLC · Phase 1 · not yet recruiting
- NCT06015568 — Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive · Phase 1 · not yet recruiting
- NCT05869240 — BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03396185 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Betta Pharmaceuticals Co., Ltd.
- Last refreshed: 18 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03396185.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing